The project has 6 partners and focuses on Chronic Lymphocytic Leukemia (CLL), a common cancer and the most frequent type of leukemia in Western countries. The clinical course of CLL is highly diverse, ranging from death within 2-3 years to indolent disease. The disease is driven by a combination of genetic defects and interactions of the malignant cells with various cellular elements or soluble factors from the microenvironment. The main objective of this project is to determine the role of these factors in conferring resistance to novel targeted therapies and identify rationale therapeutic combinations to prevent or overcome this resistance.
Duration: 2016-2019
Donor/funding programme:
MIUR-TRANSCAN/ ERA-NET TRANSCAN-2
Partners:
Dimitar Efremov Molecular Hematology, ICGEB Trieste, Italy
Academisch Medisch Centrum bij de Universiteit van Amsterdam, The Netherlands
Genuinnutzige Salzburger Landesliniken BetriebsgesmbH, Austria
Weizmann Insitute of Science, Israel
Ulm University, Germany
German Cancer Research Centre, Germany
Institut Natuional de la Sante et de la Recherche Medicale, France